Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00778401 · ClinicalTrials.gov registry record · NA
Bioequivalence Study of Gabapentin 800 mg Tablets Under Fasting Conditions
A NA study, sponsored by Ranbaxy Laboratories Limited.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT00778401: Completed NA study, sponsored by Ranbaxy Laboratories Limited.
NCT00778401 is a NA study that has completed, run by Ranbaxy Laboratories Limited. The registered enrollment target is 28 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00778401, a NA study, has completed, sponsored by Ranbaxy Laboratories Limited.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study compared the relative bioavailability (rate and extent of absorption) of the test Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited to the reference Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd., distributed by Parke Davis, division of Warner-Lambert Co. in 28 healthy, adult subjects (21 males and 7 females) under fasting conditions using randomized, two-way crossover design.
Interventions
- DRUG Gabapentin tablets 800 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2002-10 |
| Est. Completion | 2002-12 |
| Phase | NA |
What the finished NCT00778401 record still lists
NCT00778401 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Gabapentin tablets 800 mg is the first listed.
NCT00778401 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00778401 about?
NCT00778401 is a clinical study titled "Bioequivalence Study of Gabapentin 800 mg Tablets Under Fasting Conditions". This study compared the relative bioavailability (rate and extent of absorption) of the test Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited to the reference Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd., distributed by Parke Davis, division of Warner-Lambert Co. in 28 hea...
What is the current status of trial NCT00778401?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2002-10. Estimated completion is 2002-12.
What interventions are being tested in trial NCT00778401?
The interventions under investigation include: Gabapentin tablets 800 mg (DRUG).
Who is sponsoring clinical trial NCT00778401?
This trial is sponsored by Ranbaxy Laboratories Limited, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00778401's enrollment target sits among peer trials
28 1704th of 2000 higher than 293 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia